NAVIGATION
Translational Research
Further Information
Recent Webinar:
In Vivo Imaging: Targeted Fluorescent Contrast Agents for Image-Guided Cancer Surgery
- Dr. D. Michael Olive,
VP Translational Research
Dutch Clinical Trial: NL37479.042.11
Validation of Uptake of a VEGF-targeted Optical Fluorescent Imaging Tracer in Surgical Specimens of Breast Cancer and Application of Pre- and Intra-operative Human Molecular Fluorescence Imaging Techniques. A multicenter feasibility study.
Email:
Translational.Research@licor.com
Phone:
(1) 402-467-0904
For preclinical research:
IRDye infrared dyes and imaging probes can be purchased on our Biotechnology website.
LI-COR Translational Research is working to facilitate the use of IRDye® 800CW-labeled imaging agents in clinical studies for fluorescence-assisted cancer surgery. In preclinical studies, IRDye 800CW has been conjugated to a variety of targeted agents by a number of leading molecular imaging laboratories with the intent to translate these to clinical use. LI-COR has completed manufacturing of IRDye® 800CW NHS ester under a GMP process and the dye is the subject of a published toxicity study. A drug master file is on record with European regulatory authorities in support of a clinical trial. These are key steps toward translating near-infrared contrast agents into clinical use.
LI-COR interviewed Dr. Go van Dam, a surgeon specializing in oncology at the Groningen University Medical Center in the Netherlands. A key focus of van Dam’s research is to explore new tools such as targeted fluorescent imaging probes that will help address the challenges facing oncology surgeons. He discusses his research using near-infrared fluorescent imaging during surgery to improve cancer patient outcomes.
